Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Nov;81(6):1059–1065. doi: 10.1038/sj.bjc.6690807

Evaluation of seven tumour markers in pleural fluid for the diagnosis of malignant effusions

M Miédougé 1, P Rouzaud 2, G Salama 1, M-C Pujazon 2, C Vincent 1, M-A Mauduyt 1, J Reyre 1, P Carles 2, G Serre 1
PMCID: PMC2362942  PMID: 10576665

Abstract

Carcinoembryonic antigen (CEA), carbohydrate antigens 15–3, 19–9 and 72–4 (CA 15–3, CA 19–9 and CA 72–4), cytokeratin 19 fragments (CYFRA 21–1), neuron-specific enolase (NSE) and squamous cell carcinoma antigen (SCC) were evaluated in pleural fluid for the diagnosis of malignant effusions. With a specificity of 99%, determined in a series of 121 benign effusions, the best individual diagnostic sensitivities in the whole series of 215 malignant effusions or in the subgroup of adenocarcinomas were observed with CEA, CA 15–3 and CA 72–4. As expected, a high sensitivity was obtained with SCC in squamous cell carcinomas and with NSE in small-cell lung carcinomas. CYFRA and/or CA 15–3 were frequently increased in mesotheliomas. Discriminant analysis showed that the optimal combination for diagnosis of non-lymphomatous malignant effusions was CEA + CA 15–3 + CYFRA + NSE: sensitivity of 94.4% with an overall specificity of 95%. In malignant effusions with a negative cytology, 83.9% were diagnosed using this association. The association CYFRA + NSE + SCC was able to discriminate adenocarcinomas from small-cell lung cancers. Regarding their sensitivity and their complementarity, CEA, CA 15–3, CYFRA 21–1, NSE and SCC appear to be very useful to improve the diagnosis of malignant pleural effusions. © 1999 Cancer Research Campaign

Keywords: tumour markers, pleural effusions, carcinomas

Full Text

The Full Text of this article is available as a PDF (93.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Asseo P. P., Tracopoulos G. D. Simultaneous enzyme immunoassay of carcinoembryonic antigen in pleural effusion and serum. Am J Clin Pathol. 1982 Jan;77(1):66–71. doi: 10.1093/ajcp/77.1.66. [DOI] [PubMed] [Google Scholar]
  2. Brown G. A., Ginsberg P. C., Harkaway R. C. Prostatic adenocarcinoma diagnosed by prostate-specific antigen analysis of pleural fluid. Urol Int. 1998;60(3):197–198. doi: 10.1159/000030252. [DOI] [PubMed] [Google Scholar]
  3. Callet N., Cohen-Solal Le Nir C. C., Berthelot E., Pichon M. F. Cancer of the uterine cervix: sensitivity and specificity of serum Cyfra 21.1 determinations. Eur J Gynaecol Oncol. 1998;19(1):50–56. [PubMed] [Google Scholar]
  4. Cascinu S., Del Ferro E., Barbanti I., Ligi M., Fedeli A., Catalano G. Tumor markers in the diagnosis of malignant serous effusions. Am J Clin Oncol. 1997 Jun;20(3):247–250. doi: 10.1097/00000421-199706000-00007. [DOI] [PubMed] [Google Scholar]
  5. Daste G., Serre G., Mauduyt M. A., Vincent C., Caveriviere P., Soleilhavoup J. P. Immunophenotyping of mesothelial cells and carcinoma cells with monoclonal antibodies to cytokeratins, vimentin, CEA and EMA improves the cytodiagnosis of serous effusions. Cytopathology. 1991;2(1):19–28. doi: 10.1111/j.1365-2303.1991.tb00380.x. [DOI] [PubMed] [Google Scholar]
  6. Doweck I., Barak M., Greenberg E., Uri N., Kellner J., Lurie M., Gruener N. Cyfra 21-1. A new potential tumor marker for squamous cell carcinoma of head and neck. Arch Otolaryngol Head Neck Surg. 1995 Feb;121(2):177–181. doi: 10.1001/archotol.1995.01890020039009. [DOI] [PubMed] [Google Scholar]
  7. Fenton K. N., Richardson J. D. Diagnosis and management of malignant pleural effusions. Am J Surg. 1995 Jul;170(1):69–74. doi: 10.1016/s0002-9610(99)80257-8. [DOI] [PubMed] [Google Scholar]
  8. Ferrer J. S., Muñoz X. G., Orriols R. M., Light R. W., Morell F. B. Evolution of idiopathic pleural effusion: a prospective, long-term follow-up study. Chest. 1996 Jun;109(6):1508–1513. doi: 10.1378/chest.109.6.1508. [DOI] [PubMed] [Google Scholar]
  9. Ferroni P., Szpak C., Greiner J. W., Simpson J. F., Guadagni F., Johnston W. W., Colcher D. CA 72-4 radioimmunoassay in the diagnosis of malignant effusions. Comparison of various tumor markers. Int J Cancer. 1990 Sep 15;46(3):445–451. doi: 10.1002/ijc.2910460320. [DOI] [PubMed] [Google Scholar]
  10. Garcia-Pachon E., Padilla-Navas I., Dosda M. D., Miralles-Llopis A. Elevated level of carcinoembryonic antigen in nonmalignant pleural effusions. Chest. 1997 Mar;111(3):643–647. doi: 10.1378/chest.111.3.643. [DOI] [PubMed] [Google Scholar]
  11. Grem J. The prognostic importance of tumor markers in adenocarcinomas of the gastrointestinal tract. Curr Opin Oncol. 1997 Jul;9(4):380–387. doi: 10.1097/00001622-199709040-00012. [DOI] [PubMed] [Google Scholar]
  12. Guadagni F., Roselli M., Cosimelli M., Ferroni P., Spila A., Cavaliere F., Casaldi V., Wappner G., Abbolito M. R., Greiner J. W. CA 72-4 serum marker--a new tool in the management of carcinoma patients. Cancer Invest. 1995;13(2):227–238. doi: 10.3109/07357909509011692. [DOI] [PubMed] [Google Scholar]
  13. Hanley J. A., McNeil B. J. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983 Sep;148(3):839–843. doi: 10.1148/radiology.148.3.6878708. [DOI] [PubMed] [Google Scholar]
  14. Harris R. J., Kavuru M. S., Rice T. W., Kirby T. J. The diagnostic and therapeutic utility of thoracoscopy. A review. Chest. 1995 Sep;108(3):828–841. doi: 10.1378/chest.108.3.828. [DOI] [PubMed] [Google Scholar]
  15. Klockars M., Lindgren J., Pettersson T., Hellström P. E., Norhagen A. Carcinoembryonic antigen in pleural effusions: a diagnostic and prognostic indicator. Eur J Cancer. 1980 Sep;16(9):1149–1152. doi: 10.1016/0014-2964(80)90173-5. [DOI] [PubMed] [Google Scholar]
  16. Lembersky B. C., Thomas L. C. Metastases of unknown primary site. Med Clin North Am. 1996 Jan;80(1):153–171. doi: 10.1016/s0025-7125(05)70433-8. [DOI] [PubMed] [Google Scholar]
  17. Leslie W. K., Kinasewitz G. T. Clinical characteristics of the patient with nonspecific pleuritis. Chest. 1988 Sep;94(3):603–608. doi: 10.1378/chest.94.3.603. [DOI] [PubMed] [Google Scholar]
  18. Loddenkemper R., Boutin C. Thoracoscopy: present diagnostic and therapeutic indications. Eur Respir J. 1993 Nov;6(10):1544–1555. [PubMed] [Google Scholar]
  19. MacLean G. D., Reddish M. A., Longenecker B. M. Prognostic significance of preimmunotherapy serum CA27.29 (MUC-1) mucin level after active specific immunotherapy of metastatic adenocarcinoma patients. J Immunother. 1997 Jan;20(1):70–78. doi: 10.1097/00002371-199701000-00008. [DOI] [PubMed] [Google Scholar]
  20. Menard O., Dousset B., Jacob C., Martinet Y. Improvement of the diagnosis of the cause of pleural effusion in patients with lung cancer by simultaneous quantification of carcinoembryonic antigen (CEA) and neuron-specific enolase (NSE) pleural levels. Eur J Cancer. 1993;29A(13):1806–1809. doi: 10.1016/0959-8049(93)90525-k. [DOI] [PubMed] [Google Scholar]
  21. Mezger J., Calavrezos A., Drings P., Gatzemeier U., Kaukel E., Konietzko N., Koschel G., Lamerz R., von Pawel J., Römer W. Value of serum and effusion fluid CEA levels for distinguishing between diffuse malignant mesothelioma and carcinomatous pleural metastases. Lung. 1994;172(3):183–184. doi: 10.1007/BF00175946. [DOI] [PubMed] [Google Scholar]
  22. Morita T., Kikuchi T., Hashimoto S., Kobayashi Y., Tokue A. Cytokeratin-19 fragment (CYFRA 21-1) in bladder cancer. Eur Urol. 1997;32(2):237–244. [PubMed] [Google Scholar]
  23. Niklinski J., Furman M. Clinical tumour markers in lung cancer. Eur J Cancer Prev. 1995 Apr;4(2):129–138. doi: 10.1097/00008469-199504000-00002. [DOI] [PubMed] [Google Scholar]
  24. Nyberg P., Söderblom T., Pettersson T., Riska H., Klockars M., Linko L. Neurone-specific enolase levels in pleural effusions in patients with rheumatoid arthritis. Thorax. 1996 Jan;51(1):92–94. doi: 10.1136/thx.51.1.92. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Paone G., De Angelis G., Greco S., Fiorucci F., Bisetti A., Ameglio F. Carcinoembryonic antigen, tissue polypeptide antigen and neuron-specific enolase pleural levels used to classify small-cell and non-small-cell lung cancer patients by discriminant analysis. J Cancer Res Clin Oncol. 1996;122(8):499–503. doi: 10.1007/BF01187163. [DOI] [PubMed] [Google Scholar]
  26. Peto J., Hodgson J. T., Matthews F. E., Jones J. R. Continuing increase in mesothelioma mortality in Britain. Lancet. 1995 Mar 4;345(8949):535–539. doi: 10.1016/s0140-6736(95)90462-x. [DOI] [PubMed] [Google Scholar]
  27. Plebani M., Basso D., Navaglia F., De Paoli M., Tommasini A., Cipriani A. Clinical evaluation of seven tumour markers in lung cancer diagnosis: can any combination improve the results? Br J Cancer. 1995 Jul;72(1):170–173. doi: 10.1038/bjc.1995.296. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Pujol J. L., Grenier J., Daurès J. P., Daver A., Pujol H., Michel F. B. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res. 1993 Jan 1;53(1):61–66. [PubMed] [Google Scholar]
  29. Rittgers R. A., Loewenstein M. S., Feinerman A. E., Kupchik H. Z., Marcel B. R., Koff R. S., Zamcheck N. Carcinoembryonic antigen levels in benign and malignant pleural effusions. Ann Intern Med. 1978 May;88(5):631–634. doi: 10.7326/0003-4819-88-5-631. [DOI] [PubMed] [Google Scholar]
  30. Romero S., Fernández C., Arriero J. M., Espasa A., Candela A., Martín C., Sánchez-Payá J. CEA, CA 15-3 and CYFRA 21-1 in serum and pleural fluid of patients with pleural effusions. Eur Respir J. 1996 Jan;9(1):17–23. doi: 10.1183/09031936.96.09010017. [DOI] [PubMed] [Google Scholar]
  31. Sahn S. A. State of the art. The pleura. Am Rev Respir Dis. 1988 Jul;138(1):184–234. doi: 10.1164/ajrccm/138.1.184. [DOI] [PubMed] [Google Scholar]
  32. Salama G., Miédougé M., Rouzaud P., Mauduyt M. A., Pujazon M. C., Vincent C., Carles P., Serre G. Evaluation of pleural CYFRA 21-1 and carcinoembryonic antigen in the diagnosis of malignant pleural effusions. Br J Cancer. 1998;77(3):472–476. doi: 10.1038/bjc.1998.75. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Satoh H., Sumi M., Yagyu H., Ishikawa H., Suyama T., Naitoh T., Saitoh T., Hasegawa S. Clinical evaluation of CYFRA 21-1 in malignant pleural fluids. Oncology. 1995 May-Jun;52(3):211–214. doi: 10.1159/000227459. [DOI] [PubMed] [Google Scholar]
  34. Shimokata K., Niwa Y., Yamamoto M., Sasou H., Morishita M. Pleural fluid neuron-specific enolase. A useful diagnostic marker for small cell lung cancer pleurisy. Chest. 1989 Mar;95(3):602–603. doi: 10.1378/chest.95.3.602. [DOI] [PubMed] [Google Scholar]
  35. Sölétormos G., Nielsen D., Schiøler V., Skovsgaard T., Dombernowsky P. Tumor markers cancer antigen 15.3, carcinoembryonic antigen, and tissue polypeptide antigen for monitoring metastatic breast cancer during first-line chemotherapy and follow-up. Clin Chem. 1996 Apr;42(4):564–575. [PubMed] [Google Scholar]
  36. Toumbis M., Rasidakis A., Passalidou E., Kalomenidis J., Alchanatis M., Orphanidou D., Jordanoglou J. Evaluation of CYFRA 21-1 in malignant and benign pleural effusions. Anticancer Res. 1996 Jul-Aug;16(4A):2101–2104. [PubMed] [Google Scholar]
  37. Villena V., López Encuentra A., Rodríguez F. P. False-positive results of carcinoembryonic antigen in pleural effusions. Chest. 1998 Apr;113(4):1143–1144. doi: 10.1378/chest.113.4.1143-a. [DOI] [PubMed] [Google Scholar]
  38. Villena V., López-Encuentra A., Echave-Sustaeta J., Martín-Escribano P., Ortuño-de-Solo B., Estenoz-Alfaro J. Diagnostic value of CA 72-4, carcinoembryonic antigen, CA 15-3, and CA 19-9 assay in pleural fluid. A study of 207 patients. Cancer. 1996 Aug 15;78(4):736–740. doi: 10.1002/(SICI)1097-0142(19960815)78:4<736::AID-CNCR7>3.0.CO;2-C. [DOI] [PubMed] [Google Scholar]
  39. Zeimet A. G., Marth C., Offner F. A., Obrist P., Uhl-Steidl M., Feichtinger H., Stadlmann S., Daxenbichler G., Dapunt O. Human peritoneal mesothelial cells are more potent than ovarian cancer cells in producing tumor marker CA-125. Gynecol Oncol. 1996 Sep;62(3):384–389. doi: 10.1006/gyno.1996.0253. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES